almagate has been researched along with Proteinuria in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamis, AP; Apte, RS; Masonson, H; Modi, M; Patel, M; Whitfield, L | 1 |
| Hernández, C; Simó, R | 1 |
1 review(s) available for almagate and Proteinuria
| Article | Year |
|---|---|
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Diabetic Retinopathy; Humans; Hypertension; Proteinuria; Vascular Endothelial Growth Factor A | 2008 |
1 trial(s) available for almagate and Proteinuria
| Article | Year |
|---|---|
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Blood Pressure; Choroidal Neovascularization; Double-Blind Method; Female; Half-Life; Humans; Immunoglobulin G; Immunoglobulin M; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Prospective Studies; Proteinuria; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |